Infliximab Biosimilar - Research Grade
Bulk Infliximab Biosimilar - Research Grade
Product Benefits:ichorbio's infliximab Biosimilar - Research Grade is manufactured in a cGMP compliant facility.
Size:ichorbio's research grade infliximab biosimilar is available in the following sizes: 5mg, 10mg, 20mg, 50mg, 100mg ichorbio regularly manufactures bulk multi-gram amounts of our infliximab biosimilar - please contact us for pricing.
Target:TNF-alpha
Clone:n/a
Isotype:IgG1 kappa
Other Names: Host:Humanized
Species Reactivity:Human
Specificity:Detects human TNF-alpha.
Purification Method:This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background:Infliximab biosimilar is a chimeric IgG1κ monoclonal antibody (composed of human constant and murine variable regions) specific for human tumor necrosis factor-alpha (TNFα). It has a molecular weight of approximately 149.1 kilodaltons. Infliximab biosimilar is produced by a recombinant cell line cultured by suspension culture and is purified by a series of steps that includes measures to inactivate and remove viruses.
Concentration:1.0 - 5.0 mg/ml
Formulation:Sterile, clear, colorless, preservative-free solution with a pH of about 7.2, containing dihydrate Disodium hydrogen phosphate, sodium dihydrogen phosphate monohydrate, polysorbate 80, and sucrose.
Purity:>95% by SDS-PAGE and HPLC
Endotoxin:≤ 0.75 EU/mg as determined by the LAL method
Storage:Infliximab Biosimilar - Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Applications:Functional Assays
Application Notes:Each investigator should determine their own optimal working dilution for specific applications.
Use: ichorbio's infliximab biosimilar is for research use only. Isotype Control:Concentration | 10.27mg/ml |
---|---|
isotype | IgG1 kappa |
Host | Humanized |